First National Bank of Omaha lessened its stake in shares of Allergan plc (NYSE:AGN) by 22.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 42,696 shares of the company’s stock after selling 12,174 shares during the quarter. First National Bank of Omaha’s holdings in Allergan were worth $6,984,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of AGN. Cable Hill Partners LLC increased its holdings in Allergan by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after buying an additional 370 shares during the period. Rockefeller Financial Services Inc. increased its holdings in Allergan by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after buying an additional 400 shares during the period. BB&T Investment Services Inc. increased its holdings in Allergan by 1,308.2% in the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after buying an additional 641 shares during the period. Phocas Financial Corp. bought a new position in Allergan in the 2nd quarter valued at about $150,000. Finally, Acropolis Investment Management LLC bought a new position in Allergan in the 4th quarter valued at about $153,000. Institutional investors own 79.76% of the company’s stock.
In related news, Chairman Brent L. Saunders acquired 4,600 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The shares were bought at an average cost of $164.74 per share, for a total transaction of $757,804.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Meury sold 11,807 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Over the last three months, insiders bought 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.
Allergan plc (NYSE:AGN) traded up $7.91 during midday trading on Wednesday, hitting $166.63. 4,798,123 shares of the stock traded hands, compared to its average volume of 3,166,290. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.88 and a current ratio of 2.04. The company has a market cap of $52,790.00, a price-to-earnings ratio of -13.82, a price-to-earnings-growth ratio of 1.16 and a beta of 1.19. Allergan plc has a 12-month low of $156.00 and a 12-month high of $256.80.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. The company had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm earned $3.90 EPS. equities analysts forecast that Allergan plc will post 15.56 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.73%. This is an increase from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s dividend payout ratio is presently -23.35%.
Several equities research analysts recently issued reports on AGN shares. Cantor Fitzgerald set a $191.00 target price on shares of Allergan and gave the stock a “hold” rating in a research report on Tuesday, December 12th. Vetr downgraded shares of Allergan from a “hold” rating to a “sell” rating and set a $180.97 price target on the stock. in a research report on Monday, January 22nd. Credit Suisse Group set a $243.00 price target on shares of Allergan and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. Citigroup dropped their price target on shares of Allergan from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Thursday, October 19th. Finally, Bank of America boosted their price target on shares of Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $227.23.
TRADEMARK VIOLATION NOTICE: “Allergan plc (NYSE:AGN) Shares Sold by First National Bank of Omaha” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/allergan-plc-agn-shares-sold-by-first-national-bank-of-omaha.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.